Skip to main content
Clinical Trials/NCT06406855
NCT06406855
Recruiting
Not Applicable

Brain-Controlled Spinal Stimulation Therapy for Restoration of Walking After Incomplete Spinal Cord Injury (SCI)

University of Miami1 site in 1 country12 target enrollmentMay 7, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Spinal Cord Injuries
Sponsor
University of Miami
Enrollment
12
Locations
1
Primary Endpoint
Number of related neurological deterioration (LEMS)
Status
Recruiting
Last Updated
7 months ago

Overview

Brief Summary

The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).

Registry
clinicaltrials.gov
Start Date
May 7, 2024
End Date
December 31, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Matija Milosevic

Assistant Professor

University of Miami

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old and no older than 70 years old at the time of enrollment.
  • Traumatic incomplete spinal cord injury (neurological level at or above T10 spinal cord level; Abbreviated Injury Scale (AIS) C or D impairment grade for group 1, 3 and 4 and AIS B, C or D impairment grade for group 2), who are more than 6 months post-injury.
  • Has detectable motor function in at least 2 muscles per side confirmed by voluntary Electromyography (EMG) or detectable tibialis anterior (TA) muscle motor evoked potentials (MEPs) at the baseline assessment.
  • Able to commit to intensive training and assessment sessions over a maximum total duration of 6 months.
  • Could effectively walk overground for at least 10 meters with some assistance of a therapist and minimal body-weight support, with functional spasticity (by participant's self-report), functional range-of-motion of lower limb joints, and acceptable bone mass to enable body-weight support, confirmed by Dual-energy X-ray absorptiometry (DXA) scan.

Exclusion Criteria

  • Has traumatic brain injury, stroke, multiple sclerosis, or other neuromuscular disorders that could affect neuromotor function and walking.
  • Has severe spasticity that could prevent stepping and walking function determined by the investigator.
  • Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.
  • Has other contra-indications for transcranial magnetic stimulation (TMS) or Transcutaneous Spinal Cord Stimulation (TSCS).
  • Has a history of recent seizures or poorly managed autonomic dysreflexia that could be triggered by TMS or TSCS.
  • Has a history of prior intracranial surgery or known lesions that would limit TMS assessments and Brain-Computer Interface (BCI) recordings.
  • Individuals with metal implants in their head and other implantable devices in the body that could be affected by TMS or TSCS.
  • Has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).
  • Has urinary tract infection, unhealed fracture, contracture, and pressure sore (Braden Scale).
  • Has breakdown in skin area that will come into contact with electrodes.

Outcomes

Primary Outcomes

Number of related neurological deterioration (LEMS)

Time Frame: up to 12 months

Lower Extremity Motor Score (LEMS) to assess lower limb muscle function following the American Spinal Injury Association Impairment Scale (ASIA) guidelines. The LEMS evaluates motor function on a scale of 0 (no motor function) to 5 (full motor function).

Number of subjects that complete the study

Time Frame: up to 12 months

Safety will be determined by number of subjects that complete the study, as designed.

Walking function using 10 meter walk test (10MWT)

Time Frame: up to 12 months

This is a test of short-distance walking function. The subject will be asked to walk at a comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway. Time is measured in meters per seconds.

Number of treatment related incidence of adverse events (AEs)

Time Frame: up to 12 months

Safety will be reported as the incidence of treatment related AEs as assessed by the study doctor

Walking function using 6 minute walk test (6MWT)

Time Frame: up to 12 months

The object of the test is to walk as far as possible for 6 minutes. The subject will walk at a normal pace around a marked course for 6 minutes. The subject may stop to rest and begin again at will. The distance covered indicates aerobic fitness. The further a subject walks, the better their cardiovascular condition. Units are measured in meters.

Secondary Outcomes

  • Mobility measured by Timed Up and Go (TUG) Test(up to 12 months.)
  • Balance measured by the Berg Balance Scale (BBS)(up to 12 months.)
  • Muscular spasticity measured by the Modified Ashworth Scale (MAS)(up to 12 months.)
  • Independence as measured by Spinal Cord Independence Measure (SCIM III)(up to 12 months)
  • Quality of Life measured by the Reintegration to Normal Living (RNL) questionnaires(up to 12 months)
  • Muscular spasticity measured by the Pendulum Test(up to 12 months.)
  • Walking assistance measured by the Walking Index for Spinal Cord Injury Scale (WISCI II)(up to 12 months)
  • Quality of Life using the International Spinal Cord Injury - Quality of Life (ISCI-QOL)(up to 12 months)

Study Sites (1)

Loading locations...

Similar Trials